<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03708965</url>
  </required_header>
  <id_info>
    <org_study_id>JR-141-BR22</org_study_id>
    <nct_id>NCT03708965</nct_id>
  </id_info>
  <brief_title>An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II</brief_title>
  <official_title>An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JCR Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JCR Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase II open-label, parallel group, 2 sites (Brazil), designed to evaluate the long term&#xD;
      safety and efficacy of study drug for the treatment of the MPS II.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary heparan sulfate concentrations</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary dermatan sulfate concentrations</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum heparan sulfate concentrations</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum dermatan sulfate concentrations</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver and spleen volumes (MRI)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Mucopolysaccharidosis II</condition>
  <arm_group>
    <arm_group_label>JR-141</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be assigned to 1.0, 2.0 or 4.0 mg of JR-141 per kg of body weight once every week (the same dose taken during the previous study) in the beginning of the study.&#xD;
During the study, the dose of all subjects will be switched to the selected one.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JR-141</intervention_name>
    <description>IV infusion (lyophilized powder)</description>
    <arm_group_label>JR-141</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who will have completed clinical trial JR-141-BR21.&#xD;
&#xD;
          -  Capable of providing written consent by himself, unless the patient is under the age&#xD;
             of 18 years at the time of informed consent process, or it is not possible to obtain&#xD;
             consent from the patient himself due to his intellectual disabilities associated with&#xD;
             MPS II.&#xD;
&#xD;
          -  In the case of a patient who is under the age of 18 years or from whom it is not&#xD;
             possible to obtain consent due to his intellectual disabilities associated with MSP&#xD;
             II, he may be included if written consent can be provided by legal representative;&#xD;
             however written consent should be obtained from the patient himself too, wherever&#xD;
             possible.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to sign the informed consent form.&#xD;
&#xD;
          -  Unable to perform the study procedures, except for neurocognitive testing.&#xD;
&#xD;
          -  Previous engrafted BMT/HSCT.&#xD;
&#xD;
          -  Judged by the investigator or subinvestigator as being unable to undergo lumbar&#xD;
             puncture, including those who have difficulties in taking a position for lumber&#xD;
             puncture due to joint contracture or those who are likely to experience difficulty&#xD;
             breathing during the lumbar puncture process.&#xD;
&#xD;
          -  Judged by the investigator or subinvestigator to be ineligible to participate in the&#xD;
             study due to a history of a serious drug allergy or sensitivity.&#xD;
&#xD;
          -  Otherwise judged by the investigator or subinvestigator to be ineligible to&#xD;
             participate in the study out of consideration for the subject safety.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Grupo de Pesquisa Clínica em Genética Médica - HCPA</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Igeim - Unifesp</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 27, 2018</study_first_submitted>
  <study_first_submitted_qc>October 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
    <mesh_term>Mucopolysaccharidoses</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

